[8-K] Quince Therapeutics, Inc. Reports Material Event
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Quince Therapeutics, Inc. has regained compliance with Nasdaq’s continued listing standards. Nasdaq staff reviewed the company’s Form 10-Q for the quarter ended March 31, 2026, which reported stockholders’ equity of $15,672,000, and determined that Quince now meets Nasdaq Listing Rule 5450(b)(1)(A).
This closes a prior deficiency notice issued on March 17, 2026, when Quince had failed to maintain a minimum market value of listed securities of $50,000,000 over 30 consecutive business days. Nasdaq has confirmed that the compliance matter is now closed and the company remains listed on the Nasdaq Global Select Market.
Positive
- Nasdaq compliance restored: Nasdaq staff confirmed Quince meets Listing Rule 5450(b)(1)(A) with stockholders’ equity of $15,672,000, closing a prior deficiency notice tied to the $50,000,000 market value requirement and removing immediate listing risk.
Negative
- None.
Insights
Nasdaq confirms Quince back in full compliance, removing near-term delisting risk.
Quince Therapeutics previously faced a Nasdaq deficiency notice for failing to maintain a $50,000,000 market value of listed securities over 30 days. That issue could have led to a downgrade or eventual delisting if unresolved.
Nasdaq’s May 20, 2026 letter confirms Quince now meets Listing Rule 5450(b)(1)(A) based on reported stockholders’ equity of $15,672,000 as of March 31, 2026. The matter is officially closed, meaning the company continues trading on the Nasdaq Global Select Market under existing terms.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Stockholders’ equity: $15,672,000
MVLS requirement: $50,000,000
Listing rule satisfied: Nasdaq Listing Rule 5450(b)(1)(A)
+2 more
5 metrics
Stockholders’ equity
$15,672,000
Reported in Form 10-Q for quarter ended March 31, 2026
MVLS requirement
$50,000,000
Minimum market value of listed securities over 30 consecutive business days
Listing rule satisfied
Nasdaq Listing Rule 5450(b)(1)(A)
Used by Nasdaq to confirm continued listing compliance
Prior deficiency date
March 17, 2026
Date Nasdaq notified Quince of MVLS non-compliance
Compliance confirmation date
May 20, 2026
Date Nasdaq staff letter confirmed rule 5450(b)(1)(A) compliance
Key Terms
market value of listed securities, stockholders’ equity, Nasdaq Listing Rule 5450(b)(1)(A), continued listing requirements
4 terms
market value of listed securities financial
"failed to maintain a minimum market value of listed securities (“MVLS”) of $50,000,000"
The market value of listed securities is the total worth of stocks, bonds and other tradable instruments quoted on an exchange, measured using the prices investors are willing to pay right now. It’s calculated by multiplying each security’s current market price by the number of units outstanding and adding those amounts together, like totaling the value of every item in a store at today’s prices. Investors watch this because it shows the size, liquidity and overall health of the market or a company’s publicly traded portion, and it influences index weights, fund allocations and perceived risk.
stockholders’ equity financial
"reported stockholders’ equity of $15,672,000, the Company complies with Nasdaq Listing Rule"
Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.
Nasdaq Listing Rule 5450(b)(1)(A) regulatory
"the Company complies with Nasdaq Listing Rule 5450(b)(1)(A). Accordingly, the Company has regained compliance"
continued listing requirements regulatory
"the Company has regained compliance with Nasdaq’s continued listing requirements and this matter is now closed"
Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.
FAQ
What Nasdaq issue did Quince Therapeutics (QNCX) previously face?
Quince previously received a Nasdaq notice for not maintaining a $50,000,000 market value of listed securities over 30 consecutive business days, a key requirement for continued listing on the Nasdaq Global Market.
How did Quince Therapeutics (QNCX) regain Nasdaq listing compliance?
Quince regained compliance after its Form 10-Q for the quarter ended March 31, 2026 reported stockholders’ equity of $15,672,000, satisfying Nasdaq Listing Rule 5450(b)(1)(A) based on equity instead of market value.
Which Nasdaq listing rule does Quince Therapeutics now satisfy?
Quince now complies with Nasdaq Listing Rule 5450(b)(1)(A), which focuses on stockholders’ equity. Nasdaq staff cited stockholders’ equity of $15,672,000 reported in the March 31, 2026 Form 10-Q as the basis for compliance.
Is the Nasdaq deficiency matter for Quince Therapeutics (QNCX) still open?
No. Nasdaq staff sent a letter dated May 20, 2026 stating that Quince complies with Nasdaq Listing Rule 5450(b)(1)(A). The company confirmed the continued listing matter is now closed by Nasdaq.
What financial figure was key to Quince Therapeutics’ Nasdaq compliance?
The key figure was stockholders’ equity of $15,672,000 reported in Quince’s Form 10-Q for the quarter ended March 31, 2026. Nasdaq used this amount to confirm compliance with Listing Rule 5450(b)(1)(A).